US 12,134,790 B2
Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
Tayeba Khan, Lexington, MA (US); Andre Marozsan, Killingworth, CT (US); and Kim Askew, Lincoln, MA (US)
Assigned to Inozyme Pharma, Inc., Boston, MA (US)
Appl. No. 16/648,388
Filed by Inozyme Pharma, Inc., Boston, MA (US)
PCT Filed Sep. 26, 2018, PCT No. PCT/US2018/052795
§ 371(c)(1), (2) Date Mar. 18, 2020,
PCT Pub. No. WO2019/067502, PCT Pub. Date Apr. 4, 2019.
Claims priority of provisional application 62/563,829, filed on Sep. 27, 2017.
Prior Publication US 2020/0263153 A1, Aug. 20, 2020
Int. Cl. C12N 9/16 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61P 9/10 (2006.01); C07K 19/00 (2006.01)
CPC C12N 9/16 (2013.01) [A61P 9/10 (2018.01); C07K 19/00 (2013.01); A61K 9/0019 (2013.01); A61K 45/06 (2013.01); C12Y 301/04001 (2013.01)] 25 Claims
 
1. A method for treating a human subject having hypertension, wherein said subject is not ENPP1 deficient, the method comprising administering to the subject one or more doses of a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof, wherein said administration reduces hypertension and said reduction in hypertension is independent of reduction in calcification in said subject.